VIA-2291, which is currently in Phase II development for the treatment of cardiovascular disease caused by atherosclerosis, targets inflammation in the blood vessel wall, an underlying cause of
“Our progress toward commercializing our products, and building and expanding our quality customer base, continue on target,” said William Moffitt, Nanosphere’s president and chief executive officer. “In January
“Over the last while we have faced significant challenges and, with the current economic environment, we are not currently able to continue to finance our clinical or operational
This offering is in addition to the offering Aradigm announced on February 23, 2009, relating to the sale of approximately 41 million shares of common stock for gross
Exactech plans to introduce a new knee implant as an evolution of its flagship Optetrak brand, as a result of this continued collaboration. Limited release of the new
This innovation, Radiology Imaging for the Surgical Environment (RISE), uses the company’s visualization and informatics technologies to provide a complete solution that enables real-time, interactive consultation for medical
The 510(k) application is used when there exist similar, previously cleared technologies in the marketplace. This submission follows the company’s recently cleared 510(k) for total hip arthroplasty and
The investors have agreed to purchase the shares at a purchase price of $2.67 per share resulting in gross proceeds of $7 million to Kamada. Kamada intends to
The company said that the clinical trial did not meet its co-primary endpoints, asthma control as assessed by changes from baseline in nighttime and daytime composite symptom scores,
Under the agreement, which was signed recently at World Health Organization (WHO) headquarters in Geneva, Nobilon has granted WHO a non-exclusive license to develop, register, manufacture, use and
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.